<table-wrap xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="table2" position="float"><object-id pub-id-type="doi">10.7554/eLife.32638.013</object-id><label>Table 2.</label><caption><title>Pharmacological alterations of NAD<sup>+</sup> and NADPH/NADP&#160;+&#160;in U2OS cells measured by flow cytometry.</title></caption><table frame="hsides" rules="groups"><thead><tr><th/><th colspan="4">Normalized FRET ratio (TMR/FRET)</th></tr><tr><th rowspan="2">Treatment</th><th colspan="2">NAD-Snifit</th><th colspan="2">NADP-Snifit</th></tr><tr><th>Cytosol</th><th>Mitochondria</th><th>Cytosol</th><th>Mitochondria</th></tr></thead><tbody><tr><td>Control</td><td>1.00 (&#177;0.03)</td><td>1.00 (&#177;0.02)</td><td>1.00 (&#177;0.01)</td><td>1.00 (&#177;0.01)</td></tr><tr><td>1 mM NA</td><td>0.91 (&#177;0.01)</td><td>n.d.</td><td>0.92 (&#177;0.01)</td><td>1.00 (&#177;0.01)*</td></tr><tr><td>10 mM NAM</td><td>0.92 (&#177;0.02)</td><td>n.d.</td><td>1.05 (&#177;0.01)</td><td>n.d.</td></tr><tr><td>1 mM NMN</td><td>0.82 (&#177;0.01)</td><td>n.d.</td><td>0.95 (&#177;0.01)</td><td>0.99 (&#177;0.01)*</td></tr><tr><td>1 mM NR</td><td>0.80 (&#177;0.02)</td><td>n.d.</td><td>0.96 (&#177;0.01)</td><td>1.00 (&#177;0.01)*</td></tr><tr><td>100 nM FK866</td><td>1.61 (&#177;0.06)</td><td>1.48 (&#177;0.04)</td><td>1.05 (&#177;0.01)</td><td>0.99 (&#177;0.01)*</td></tr><tr><td>1 mM 6-AN</td><td>n.d.</td><td>n.d.</td><td>0.80 (&#177;0.02)</td><td>n.d.</td></tr><tr><td>1 mM Metformin</td><td>0.89 (&#177;0.04)</td><td>1.09 (&#177;0.03)</td><td>0.90 (&#177;0.01)</td><td>0.95 (&#177;0.01)</td></tr><tr><td>1 mM Phenformin</td><td>0.79 (&#177;0.05)</td><td>1.13 (&#177;0.06)</td><td>0.88 (&#177;0.01)</td><td>0.83 (&#177;0.01)</td></tr><tr><td>10 &#181;M Rotenone</td><td>0.67 (&#177;0.03)</td><td>1.08 (&#177;0.02)</td><td>0.75 (&#177;0.02)</td><td>0.80 (&#177;0.02)</td></tr><tr><td>25 &#181;M Oligomycin A</td><td>1.14 (&#177;0.03)</td><td>1.63 (&#177;0.01)</td><td>1.12 (&#177;0.03)</td><td>1.36 (&#177;0.07)</td></tr></tbody></table><table-wrap-foot><fn><p>Values represent the average of medians (&#177;s.d.) TMR/FRET ratios of three independent measurements normalized to control condition (n&#160;=&#160;3). Control: untreated cells (full growth medium with 25 mM glucose), NA: nicotinic acid, NAM: nicotinamide, NMN: nicotinamide mononucleotide, NR: nicotinamide riboside, FK866: (E)-N-[4-(1-benzoylpiperidin-4-yl)butyl]&#8722;3-(pyridin-3-yl)acrylamide, 6-AN: 6-aminonicotinamide.</p><p>*The effect of the treatment is not statistically significant compared to the control condition (Kruskal-Wallis with Dunn&#8217;s post-hoc multiple comparison test, &#945;&#160;=&#160;0.05). n.d., not determined. All compounds were also tested for interactions with the sensor in vitro (<xref ref-type="fig" rid="app1fig5">Appendix 1&#8212;figures 5</xref>, <xref ref-type="fig" rid="app1fig6">6</xref>).</p></fn></table-wrap-foot></table-wrap>